News · 9 November 2026 · an estimate revised

A heart trial found no benefit, so I've moved my estimate for drugs that calm inflammation three years later

On November 7th, 2026, the full results of ZEUS, the biggest test in years of whether calming inflammation prevents heart attacks, found no benefit. On November 9th I moved my estimate for when such drugs are in wide use from 2032 to 2035.

Can calming inflammation protect the heart? Inflammation is how the body reacts to injury, and in many older people a low level of it never quite switches off. For decades doctors have suspected that this smouldering inflammation helps cause heart attacks and strokes, quite apart from cholesterol or blood pressure. If they are right, a drug that damps it down should prevent some of them. This site follows that question as one of the treatments that would have to reach ordinary patients before medicine can start outrunning ageing.

There is already one answer, and it is a cheap one. Colchicine, an old pill for gout, cut heart attacks and strokes by about a third in a trial of 5,522 people reported in 2020, and the United States regulator approved it for that purpose in June 2023. So I already count the treatment as in use with patients. What I’m still waiting for is the next step: the drug prescribed for this purpose, in several countries, to a good share of the people it could help.

A trial that found nothing

The newest test came back on November 7th, 2026. The ZEUS trial, run by the drug maker Novo Nordisk, gave 6,376 people either a monthly injection of ziltivekimab, an antibody drug that blocks one of the body’s inflammation signals, or a dummy injection. Everyone in it already had hardened arteries, weak kidneys and signs of inflammation in the blood. After a little under three years, a heart attack, a stroke or a death from heart disease had happened to 17.6 per cent of those on the drug and 17.7 per cent of those on the dummy (the American College of Cardiology’s report). The drug did lower inflammation in the blood. It just did not prevent the events. The results were presented at the American Heart Association’s yearly meeting and published the same day in the New England Journal of Medicine, confirming what the company had announced in July.

The trial’s leader, the heart researcher Paul Ridker, does not read this as the end of the idea. In his hospital’s release he points out that the people in ZEUS were about ten years older and sicker than in an earlier trial where a similar drug did work, so their disease may have gone too far for any drug to turn back. He also says colchicine, which is proven, is not being prescribed as often as it should be.

Why the estimate moved

When I first set the estimate, in October 2026, I expected drugs like this to be in wide use most likely by 2032. Part of that rested on a second, newer drug arriving and pushing the whole approach into everyday care, and ziltivekimab was the most likely candidate. It is still being tested in heart failure and just after a heart attack, but those results are not expected until 2027 (the company’s announcement), so an approval for preventing heart attacks is years away at best.

It is also the second disappointment in two years: a large colchicine trial in people who had just had a heart attack found no benefit in 2025 (the treatment’s page has both). That leaves wide use resting on colchicine alone, a drug its own advocates say is under-used. So on November 9th, 2026, I moved the most likely year for wide use from 2032 to 2035, the earliest from 2027 to 2028, and the latest from 2050 to 2055 (the reasons, on the treatment’s page).

The main estimate on the site, the year medicine starts outrunning ageing, is worked out from the year a treatment first reaches patients, which for colchicine was 2023, so this change does not touch it (how the year is worked out).

The record: A drug that acts only on inflammation is approved to prevent heart attacks · the reading of 9 November 2026 · the story entry.

Sources: Ridker and others, the full ZEUS report, New England Journal of Medicine, November 7th, 2026 · American College of Cardiology, its report of the ZEUS presentation, November 7th, 2026 · Mass General Brigham, its release on the ZEUS results, November 7th, 2026 · Novo Nordisk, its announcement of the ZEUS top-line result, July 31st, 2026.

Follow the news: the feed · @SentHorizons on X · r/SentientHorizons on Reddit.